Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;33(8):2102-2104.
doi: 10.1038/s41375-019-0437-5. Epub 2019 Mar 7.

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

Xiaoyuan He  1 , Xia Xiao  2 , Qing Li  2 , Yanyu Jiang  2 , Yaqing Cao  3 , Rui Sun  3 , Xin Jin  1 , Ting Yuan  2 , Juanxia Meng  2 , Li Ma  2 , Wenyi Lu  2 , Cuicui Lyu  2 , Kaiqi Liu  4 , Mingfeng Zhao  5   6
Affiliations

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL

Xiaoyuan He et al. Leukemia. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Clinical response, expansion and persistence of anti-CD19chimeric antigen receptor (CAR)-T cells. a–c Cell counts of CAR-T cells and tumor cells in the cerebrospinal fluid (CSF) before and after CAR-T infusion. The black arrows indicate intrathecal chemotherapy. d Malignant cells in the bone marrow (BM) of patient 2 and patient 3 pre and post-infusion. e The peak expansion levels of CAR-T cells in the peripheral blood (PB), BM, and CSF
See this image and copyright information in PMC

References

    1. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–35. doi: 10.1182/blood-2013-11-492231. - DOI - PMC - PubMed
    1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. doi: 10.1056/NEJMoa1407222. - DOI - PMC - PubMed
    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28. doi: 10.1016/S0140-6736(14)61403-3. - DOI - PMC - PubMed
    1. Xiao X, He X, Li Q, Zhang H, Meng J, Jiang Y, et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-t cell infusion: a case report. Clin Cancer Res. 2019;25:29–34. doi: 10.1158/1078-0432.CCR-18-1379. - DOI - PubMed
    1. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4:e1027469. doi: 10.1080/2162402X.2015.1027469. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances